share_log

Alaunos Therapeutics Analyst Ratings

Benzinga ·  Aug 15, 2023 10:42
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/15/2023 Laidlaw & Co. Downgrades Buy → Hold
05/15/2023 934.48% HC Wainwright & Co. → $1.5 Upgrades Neutral → Buy
03/27/2023 1968.97% Wells Fargo → $3 Assumes → Overweight
10/04/2022 1968.97% Wells Fargo → $3 Assumes → Overweight
07/15/2022 1968.97% Cantor Fitzgerald → $3 Assumes → Overweight
05/04/2022 1968.97% Wells Fargo → $3 Upgrades Equal-Weight → Overweight

What is the target price for Alaunos Therapeutics (TCRT)?

The latest price target for Alaunos Therapeutics (NASDAQ: TCRT) was reported by Laidlaw & Co. on August 15, 2023. The analyst firm set a price target for $0.00 expecting TCRT to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Alaunos Therapeutics (TCRT)?

The latest analyst rating for Alaunos Therapeutics (NASDAQ: TCRT) was provided by Laidlaw & Co., and Alaunos Therapeutics downgraded their hold rating.

When is the next analyst rating going to be posted or updated for Alaunos Therapeutics (TCRT)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alaunos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alaunos Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Is the Analyst Rating Alaunos Therapeutics (TCRT) correct?

While ratings are subjective and will change, the latest Alaunos Therapeutics (TCRT) rating was a downgraded with a price target of $0.00 to $0.00. The current price Alaunos Therapeutics (TCRT) is trading at is $0.14, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment